PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

This study is testing a combination of three drugs — PD-L1 t-haNK cells, NAI IL-15sa, and cetuximab — for people with head and neck squamous cell carcinoma (HNSCC) that has returned or spread and cannot be cured surgically. These are cancers of the mouth, throat, voice box, or nasal cavity that have not responded to prior treatments. **You may be eligible if...** - You have confirmed recurrent or metastatic head and neck squamous cell carcinoma from any site in the head or neck - You have at least one measurable tumor on scans - You have received 1–2 prior treatments for recurrent/metastatic disease, including at least one anti-PD-1/PD-L1 immunotherapy - You are 18 or older - You have documentation of your tumor's PD-L1 expression level **You may NOT be eligible if...** - You have had more than 2 prior treatments for your recurrent/metastatic disease - You have not yet recovered from side effects of prior therapy - Your performance status or organ function does not meet the study requirements Talk to your doctor to see if this trial is right for you.